CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37315144.
- Also identified by DOI 10.1126/sciadv.adf0661 and PMC identifier 10266721.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B<sub>mem</sub>) cells have variation in the neutralizing activities. Here, by combining single B<sub>mem</sub> cell profiling with antibody functional assessment, we dissected the phenotype of B<sub>mem</sub> cell harboring the potently neutralizing antibodies in coronavirus disease 2019 (COVID-19)-convalescent individuals. The neutralizing subset was marked by an elevated CD62L expression and characterized by distinct epitope preference and usage of convergent V<sub>H</sub> (variable region of immunoglobulin heavy chain) genes, accounting for the neutralizing activities. Concordantly, the correlation was observed between neutralizing antibody titers in blood and CD62L<sup>+</sup> subset, despite the equivalent RBD binding of CD62L<sup>+</sup> and CD62L<sup>-</sup> subset. Furthermore, the kinetics of CD62L<sup>+</sup> subset differed between the patients who recovered from different COVID-19 severities. Our B<sub>mem</sub> cell profiling reveals the unique phenotype of B<sub>mem</sub> cell subset that harbors potently neutralizing BCRs, advancing our understanding of humoral protection.
Medical subject headings
- B-Lymphocyte Subsets
- COVID-19
- L-Selectin